Article thumbnail

Lysosomotropic agents as HCV entry inhibitors

By Usman A Ashfaq, Tariq Javed, Sidra Rehman, Zafar Nawaz and Sheikh Riazuddin

Abstract

HCV has two envelop proteins named as E1 and E2 which play an important role in cell entry through two main pathways: direct fusion at the plasma membrane and receptor-mediated endocytosis. Fusion of the HCV envelope proteins is triggered by low pH within the endosome. Lysosomotropic agents (LA) such as Chloroquine and Ammonium chloride (NH4Cl) are the weak bases and penetrate in lysosome as protonated form and increase the intracellular pH. To investigate the antiviral effect of LA (Chloroquine and NH4Cl) on pH dependent endocytosis, HCV pseudoparticles (HCVpp) of 1a and 3a genotype were produced and used to infect liver cells. The toxicological effects of Chloroquine and NH4Cl were tested in liver cells through MTT cell proliferation assay. For antiviral screening of Chloroquine and NH4Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer. The results demonstrated that Chloroquine and NH4Cl showed more than 50% reduction of virus infectivity at 50 μM and 10 mM concentrations respectively. These results suggest that inhibition of HCV at fusion step by increasing the lysosomal pH will be better option to treat chronic HCV

Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3090357
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2001). Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. Aids
  2. (1994). BC: Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey.
  3. (2007). Cassone A: Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J
  4. (2003). Cauda R: Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis
  5. (1986). Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. Nature
  6. (2003). Chronic hepatitis C virus infection. Jama
  7. (2003). Cosset FL: Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes.
  8. (1998). Dusheiko GM: Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
  9. (2005). Finch RG: Hepatitis C virus infection. Clin Microbiol Infect
  10. (2003). Fried MW: Side effects of therapy for chronic hepatitis C. Gastroenterology
  11. (1995). Group atCS: Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med
  12. (2005). hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med
  13. (1986). Ikehara Y: Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes.
  14. (2004). Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990, 6:481-489. Ashfaq et al. Virology Journal 2011, 8:163 http://www.virologyj.com/content/8/1/163 Page 5 of 627. Savarino
  15. (1997). Liriano O: Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther
  16. (1974). Lysosomotropic agents. Biochem Pharmacol
  17. (2003). McKeating JA: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA
  18. (2000). McKeating JA: The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol
  19. (2002). MP: Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep
  20. (1981). Ohkuma S: Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages.
  21. (2003). Poumbourios P: Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett
  22. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
  23. (2008). Riazuddin S: Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis
  24. (2005). ST: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J
  25. (1982). TC: Inhibition of vesicular stomatitis virus glycoprotein expression by chloroquine.
  26. (1985). Weakly basic amines inhibit the proteolytic conversion of proalbumin to serum albumin in cultured rat hepatocytes.